{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T21:38:00Z","timestamp":1758231480099,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jaad.2025.06.011","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:13:17Z","timestamp":1749582797000},"page":"1158-1160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reconsidering interferon gamma release assay thresholds and annual retesting in patients receiving biologic therapy for psoriasis"],"prefix":"10.1016","volume":"93","author":[{"given":"Annika","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Maddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-0826","authenticated-orcid":false,"given":"Kiran","family":"Motaparthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jaad.2025.06.011_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.15585\/mmwr.mm7312a4","article-title":"Tuberculosis \u2014 United States, 2023","volume":"73","author":"Williams","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2025.06.011_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.825021","article-title":"QuantiFERON-TB Gold Plus assay in patients with latent vs. active tuberculosis in a low incidence setting: level of IFN-\u03b3, CD4\/CD8 responses, and release of IL-2, IP-10, and MIG","volume":"13","author":"Carr\u00e8re-Kremer","year":"2022","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.011_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"10.1016\/j.jaad.2025.06.011_bib4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1513\/AnnalsATS.202212-1005OC","article-title":"Examining test cutoffs to optimize diagnosis of latent tuberculosis infection in people born outside the United States","volume":"20","author":"Zavala","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.jaad.2025.06.011_bib5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jaad.2022.07.051","article-title":"Reply to \u201croutine re-screening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single center retrospective cohort study.\u201d","volume":"87","author":"Khanna","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225022868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225022868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:21:21Z","timestamp":1758198081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225022868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0190962225022868"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.06.011","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reconsidering interferon gamma release assay thresholds and annual retesting in patients receiving biologic therapy for psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}